Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Classical hematology 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocytopenia 1Sarcoma 1Ovarian Neoplasms 1Osteosarcoma 1Neutropenia 1Lymphopenia 1Cytopenia 1Chondrosarcoma 1Bone Neoplasms 1Anemia 1

Interventions

pegfilgrastim 26Filgrastim 24Cyclophosphamide 8Docetaxel 7Etoposide 6pegylated granulocyte colony-stimulating factor 5Cytarabine 5eflapegrastim 4Granulocyte Colony-Stimulating Factor 4Leucovorin 3Fluorouracil 3Doxorubicin 3Cyclosporine 3Cefepime 3Caspofungin 3Carboplatin 3liposomal amphotericin B 2Vincristine 2Vancomycin 2Topotecan 2Methylprednisolone 2Methotrexate 2Itraconazole 2Irinotecan 2Ifosfamide 2Idarubicin 2Fluconazole 2Daunorubicin 2Cisplatin 2Amikacin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neutropenia × angiotensin I (1-7) × Clear all
NCT00771810 2017-11-13

Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer

Tarix Pharmaceuticals

Phase 2 Completed
34 enrolled 19 charts
Classical hematologyGynecologic

Cytopenia, Anemia, Lymphopenia, Neutropenia, Ovarian Neoplasms, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡